Compare First Citizens BancShares Inc (FCNCA) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Citizens BancShares Inc vs GeneDx Holdings Corp — how do they compare? First Citizens BancShares Inc trades at $2,162.83 (market cap $23.76B), while GeneDx Holdings Corp trades at $62.7 (market cap $1.96B). The key difference: First Citizens BancShares Inc is far larger — about 12.1× GeneDx Holdings Corp's market cap, and First Citizens BancShares Inc pays a 0.41% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| FCNCA | WGS | |
|---|---|---|
Market Cap | $23.76B | $1.96B |
Sector | Sector/Thematic | Technology |
52-Week High | $2.20K | $167.51 |
52-Week Low | $1.64K | $34.51 |
Dividend Yield | 0.41% | — |
Enterprise Value | — | $1.96B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Citizens BancShares (FCNCA) trades at $2,166.64, up 5.06% today, with a neutral technical signal and bullish moving averages. The company reported strong Q1 2026 earnings of $44.86 per share, beating estimates, and maintains a solid net income margin of 24.35%. Recent news includes a planned rebranding of Silicon Valley Bank and expansion of commercial banking capabilities.
Outlook remains stable with consistent revenue near $9.3B and profit growth. Risks include margin pressure and credit trends, but analyst consensus is a $2,320 price target with a hold-heavy rating. The stock presents a value opportunity with a low P/E of 11.94, though investor sentiment is cautious amid sector challenges.
WGS trades at $62.73, up 0.48% on the day, amid a bearish technical signal and negative earnings momentum. The stock faces significant headwinds from a class action lawsuit alleging securities fraud tied to a 49% stock decline, while fundamentals show a net loss of $21.02 million in 2025 and deteriorating profitability into 2026. Analyst consensus remains bullish with a $75.40 price target, but recent news flow is overwhelmingly negative.
The outlook is clouded by legal risks and weak financial performance, though analyst optimism suggests potential recovery if the company can stabilize operations. Key risks include litigation outcomes, execution on profitability, and market sentiment shifts. The stock's trajectory hinges on resolving legal challenges and demonstrating sustainable earnings improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About First Citizens BancShares Inc
First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.
Read more on FCNCA →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
